medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (3)


HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?

Persico M, Coppola N, Rosato V, Abenavoli L, Masarone M, De Luna A

Idioma: Ingles.
Referencias bibliográficas: 27
Paginas: 325-332
Archivo PDF: 115.28 Kb.


RESUMEN

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Zanini B, Lanzini A. Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review. Antivir Ther 2009; 14: 467-79.

  2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  3. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889-900.

  4. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, et al. A sustained virologic response is durable in patients with chronic hepatitis C with peginterferon alfa-2a and ribavirin. Gastroenterol 2010; 139: 1593-601.

  5. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic Hepatitis C: a meta-analysis. BMC Infect Dis 2012; 12: 357.

  6. de Bruijne J, Buster EHCJ, Gelderblom HC, Brouwer JT, de Knegt RJ, van Erpecum KJ, Schalm SW, et al. Treatment of chronic hepatitis C virus infection – Dutch national guidelines. Netherlands J Med 2008; 66: 311-22.

  7. McCaughan GW. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-63.

  8. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PlosOne 2014. In Press.

  9. Lawitz, E, Mangia A, Wyles D, Rodriquez-Torres M, Hassanein T, Gordon SC, Schultz M, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.

  10. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez- Torres M, Sulkowski MS, Shiffman ML, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.

  11. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.

  12. Cooper CL, Mills EJ. Therapeutic challenges in hepatitis Cinfected injection drug using patients. Harm Reduction J 2006; 3: 31.

  13. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, Cheever LW, et al. Overcoming barriers to prevention, care and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40: S276-S285.

  14. Postma MJ, Wiessing LG, Jager JC. Pharmaco-economics of drug addiction: estimating the costs of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus infection among injecting drug users in Member States of the European Union. United Nations Bulletin of Narcotics 2001; 53: 79-89.

  15. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-5.

  16. Germer JJ, Harmsen WS, Mandrekar JN, Mitchell PS, Yao JD. Evaluation of the COBAS TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J Clin Microbiol 2005; 43: 293-8.

  17. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-8.

  18. Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, Roggendorf M. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods 1994; 48: 81-92.

  19. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, Meili D, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008; 15: 747-52.

  20. Dore GJ, Hellard M, Matthews G, Grebely J, Haber PS, Petoumenos K, Yeung B, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123.

  21. Zanini B, Covolo L, Donato F, Lanzini A. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther 2010; 32: 2139-59.

  22. Gigi E, Sinakos E, Sykia A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, et al. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addict Med 2013; 7: 52-7

  23. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatol 2006; 43: 788-95.

  24. Masarone M, Persico M. Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Expert Rev Anti Infect Ther 2011; 9: 535-43.

  25. Gazdag G, Horvath G, Szabo O, Ungvari GS. Difficulties with interferon treatment in former intravenous drug users. Braz J Infect Dis 2011; 15: 163-6.

  26. Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, Jeffers L, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drog us matter? J Clin Gastroenterol 2007; 41: 199-205.

  27. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, et al. Adherence and Mental Side Effects During Hepatitis C Treatment With Interferon Alfa and Ribavirin in Psychiatric Risk Groups. Hepatology 2003; 37: 443-51.




2020     |     www.medigraphic.com